by Jason Heaviland | Nov 7, 2025 | Uncategorized
Connecting the Two Halves of the RLT Puzzle Understanding how radioligand therapy (RLT) works in cell line-derived xenograft (CDX) models requires connecting two complementary perspectives: Where the treatment goes, and What happens inside tumor cells once it gets...
by Jason Heaviland | Nov 6, 2025
Inside PRMT5: Metabolomics-Driven Insights for Cancer Therapy PRMT5 is a promising therapeutic target, especially in MTAP-deleted tumors, but measuring its inhibition has remained a challenge. In this webinar, Panome Bio scientists introduce a targeted metabolite...
by Jason Heaviland | Nov 5, 2025 | Uncategorized
Radioligand therapy (RLT) has emerged as a transformative precision oncology approach with remarkable initial response rates. However, treatment resistance remains a critical challenge that can limit long-term therapeutic success. Imaging technologies—including PET,...
by Jason Heaviland | Nov 4, 2025 | Uncategorized
The Metabolic Frontier of Neuroscience: Lessons from Alzheimer’s Disease Alzheimer’s disease is a complex, devastating neurodegenerative disorder and the most common form of dementia, affecting millions globally. While decades of research have focused on the infamous...
by ODWAdmin | Oct 30, 2025 | Uncategorized
Radioligand therapy (RLT) represents a paradigm shift in precision oncology, delivering targeted radiation directly to cancer cells while minimizing damage to healthy tissue. Cell line-derived xenograft (CDX) models serve as essential platforms for RLT development,...
